M-CSF 蛋白, Human (CHO)

M-CSF Protein, Human (CHO) is a hematopoietic growth factor with various glycosylation sites, affects survival and function of the tissue macrophages, and possesses antitumor activity.

重组人巨噬细胞集落刺激因子（CHO 表达）是一种具有多种糖基化位点的造血生长因子，影响组织巨噬细胞的存活和功能，并具有抗肿瘤活性^[1]。巨噬细胞集落刺激因子 (M-CSF) 是一种促炎细胞因子，由多种细胞类型组成，如成纤维细胞、内皮细胞、基质细胞、巨噬细胞、平滑肌细胞和成骨细胞，与其受体 CSF1R 结合，存在于多种亚型 - 作为分泌糖蛋白、细胞表面蛋白和蛋白聚糖^[2]。M-CSF 参与单核细胞/巨噬细胞谱系细胞的发育和增殖，并参与破骨细胞的诱导，破骨细胞对于骨和软骨的破坏以及类风湿性关节炎患者的关节周围骨质疏松变化非常重要^[3]。

The ED₅₀ is <5 ng/mL as measured by Murine M-NFS-60 cells, corresponding to a specific activity of >2 × 10⁵ units/mg.

• 
  Measured in a cell proliferation assay using M-NFS-60 mouse myelogenous leukemia lymphoblast cells. The ED₅₀ for this effect is 0.9606 ng/mL, corresponding to a specific activity is 1.041×10⁶ U/mg.

Human

CHO

Tag Free

P09603-3 (E33-S190)

1435  [NCBI]

EEVSEYCSHMIGSGHLQSLQRLIDSQMETSCQITFEFVDQEQLKDPVCYLKKAFLLVQDIMEDTMRFRDNTPNAIAIVQLQELSLRLKSCFTKDYEEHDKACVRTFYETPLQLLEKVKNVFNETKNLLDKDWNIFSKNCNNSFAECSSQGHERQSEGS

Approximately 18-22 kDa due to the glycosylation.

• 
  Greater than 95% as determined by reducing SDS-PAGE.

无菌粉末

Lyophilized after extensive dialysis against PBS or PBS, pH 7.4, 8% trehalose.

<0.2 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. Garnick MB, et al. Preclinical and clinical evaluation of recombinant human macrophage colony-stimulating factor (rhM-CSF). Int J Cell Cloning. 1990 Jan;8 Suppl 1:356-71.  [Content Brief]

  [2]. Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol. 2008 Jul;8(7):533-44.  [Content Brief]

  [3]. Rioja I, et al. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor. Arthritis Rheum. 2008 Aug;58(8):2257-67.  [Content Brief]